Betahistine

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Betaserc; Belgium: Bétahistine, Betaserc, Docbetahi; Bulgaria: Betaserc; Czech Republic: Avertin, Betahistin, Betaserc, Menivert, Microser, Polvertic, Serprin, Vertisan, Zenostig; Denmark: Betaserc; Estonia: Betahistin, Betaserc; Finland: Betahistin, Betaserc; France: Betahistine, Betaserc, Extovyl, Lectil, Serc; Greece: Antivom, Betaserc, Katabexin, Ribrain, Riva; Hungary: Acuver, Betagen, Betahistin, Betarevin, Betaserc, Elven, Imoxon, Microser, Polvertic, Zenostig; Ireland: Betahecon, By-Vertin, Serc, Vertigon; Italy: Microser, Vertiserc; Luxembourg: Betahistine, Betaserc, Lobione; Netherlands: Betahistine, Betakele, Betakile, Betakole, Betakule, Betalase, Betalese, Betalise, Betalose, Betaluse, Betarave, Betarive, Betarove, Betaruve, Betaserc, Divetrin, Marbeta; Poland: Betaserc, Hisitimerck, Microser; Portugal: Beta-histina, Betaserc; Romania: Acuver, Betaserc, Microser, Urutal, Vertisan, Vestibo; Slovakia: Avertin, Betahistine, Betaserc, Emperin, Microser, Polvertic, Urutal, Vertisan, Zenostig; Spain: Fidium, Serc; UK: Betahistine, Serc.

North America

Canada: Serc.

Latin America

Argentina: Betaserc, Meniex, Microser, Ronistina, Travelmín; Mexico: Serc.

Asia

Japan: Bymeniere, Convermin M, Deanosart, Histatine, Meniace, Menietol, Menitazine, Merislon, Metahislon, Metroneana, Mitapop, Papaverian, Remark, Suzutolon.

Drug combinations

Chemistry

Betahistine Hydrochloride: C~8~H~12~N~2~ 2HCl. Mw: 209.12. (1) 2-Pyridineethanamine, N-methyl-, dihydrochloride; (2) 2-[2-(Methylamino)ethyl]pyridine dihydrochloride. CAS-5579-84-0; CAS-5638-76-6 (betahistine)(1962).

Pharmacologic Category

Central Nervous System Agents, Miscellaneous; Histamine H~1~ Agonist. (ATC-Code: N07CA01).

Mechanism of action

Therapeutic use

Ménière’s disease (to decrease episodes of vertigo).

Pregnancy and lactiation implications

There are no adequate studies in pregnant women. Use only when potential benefit to the woman outweighs possible risk to fetus. Use with caution during lactation.

Unlabeled use

Contraindications

Hypersensitivity to betahistine or any component of the formulation. Peptic ulcer disease. Pheochromocytoma.

Warnings and precautions

Use with caution in cardiovascular or respiratory diseases. Avoid concurrent use with antihistamines. Not recommended for use in children.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart